The FDA has drafted guidelines for selecting the cases in which it will pursue misdemeanor prosecutions of corporate officers, holding them accountable for lingering GMP breaches and other violations of the Food, Drug and Cosmetics Act. The guidelines are being reviewed internally, reports law firm Bryan Cave, and the regulator expects to make public the final version. Item